Agenus (FRA:AJ8) Other Net Income (Loss) : €0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Agenus Other Net Income (Loss)?

Agenus's Other Net Income (Loss) for the three months ended in Mar. 2024 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Agenus's quarterly Other Net Income (Loss) declined from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) but then stayed the same from Dec. 2023 (€0.0 Mil) to Mar. 2024 (€0.0 Mil).

Agenus Other Net Income (Loss) Historical Data

The historical data trend for Agenus's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Other Net Income (Loss) Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Agenus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Agenus Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Agenus Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Agenus's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus (FRA:AJ8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

AGEN:USA AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines